159 Prediction rediction of benefit from consolidation chemotherapy for cervical cancer patients using a clinical prognostic score

Objectives The use of consolidation chemotherapy (CCT) after chemoradiation (CRT) in cervical cancer remains debatable. We evaluated the impact of CCT added to up-to-date CRT (CRT) and sought to identify predictive factors of CCT benefit. Methods This retrospective study reviewed 216 patients with 2014 FIGO stage IB2-IIA2, and IIB-IVB (para-aortic nodes only) cervical cancer treated with CRT alone or CRTT followed by CCT (CCT group). Firstly, we assessed the prognostic role of CCT. Moreover, we developed a prognostic score for distant metastasis free survival (DMFS). Results After 42.8 months of median follow up 174 patients were treated with standard CRT and 72 with CCT. Clinical characteristics were comparable between groups, except CCT patients were younger (p 1 but not for patients with score ≤1 (OS: p=0.310; DMFS: p=0.179). Conclusions A clinical score may predict CCT benefit. If this score withstands external validation, it may contribute to better selection for CCT.